Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Aclaris Therapeutics(ACRS) Newsfilter·2024-01-10 20:00Aclaris Therapeutics(ACRS) Newsfilter·2024-01-10 20:00
R1Aclaris Therapeutics(ACRS) Newsfilter·2024-01-10 20:00